CHIMERIC ANTIGEN RECEPTORS TARGETING CD70

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PANOWSKI, Siler, SRIVATSA SRINIVASAN, Surabhi, SAI, Tao, NAGARAJAN, Niranjana Aditi, PARK, Yoon, SASU, Barbra Johnson, VAN BLARCOM, Thomas John, DUSSEAUX, Mathilde Brunnhilde, GALETTO, Roman Ariel
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer). L'invention concerne des récepteurs antigéniques chimériques (CAR) qui se lient de manière spécifique à CD70. L'invention concerne également des cellules immunitaires modifiées comprenant de tels CAR, des acides nucléiques codant pour les CAR, ainsi que des procédés pour générer de tels CAR, cellules immunitaires modifiées et acides nucléiques. L'invention concerne en outre des méthodes thérapeutiques d'utilisation de ces CAR et des cellules immunes modifiées pour le traitement d'une affection associée à des cellules malignes exprimant CD70 (par exemple un cancer).